Plus   Neg

Tilray Remains Firmly Negative After Early Sell-Off

After falling sharply early in the session, shares of Tilray, Inc. (TLRY) continue to see significant weakness in afternoon trading on Wednesday. Tilray is currently down by 9.8 percent.

The steep drop by Tilray comes after the Canadian cannabis producer reported a wider third net loss on slightly weaker than expected revenues.

Tilray reported a third quarter net loss of $18.7 million or $0.20 per share compared to a loss of $1.8 million or $0.02 per share a year ago.

Excluding non-cash compensation, Tilray reported a narrower than expected loss of $0.08 per share, although its revenues of $10.0 million came in just below estimates for $10.1 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said that the current state of the COVID-19 pandemic in the U.S. is "really not good." The U.S. is the country worst-affected by the coronavirus and has recently seen a surge in coronavirus infections as lockdown restrictions are eased. Granules Pharmaceuticals, Inc. recalled twelve (12) lots of type 2 diabetes medication Metformin hydrochloride Extended-Release, in the form of oral film-coated tablets, for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Palantir Technologies Inc., the Silicon Valley big data analytics company that has handled U.S. government's certain sensitive projects, said it has confidentially filed documents with the Securities and Exchange Commission to go public. In a statement, the company said the proposed public listing of its Class A common stock is expected to take place after the SEC completes its review process.
Follow RTT